Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
2.

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.

PMID:
12189441
3.
4.

Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.

Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM.

Diabet Med. 2000 Oct;17(10):713-9.

PMID:
11110504
5.

Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes.

Daousi C, Wilding JP, Aditya S, Durham BH, Cleator J, Pinkney JH, Ranganath LR.

Clin Endocrinol (Oxf). 2009 Aug;71(2):195-201. doi: 10.1111/j.1365-2265.2008.03451.x. Epub 2008 Oct 20.

PMID:
19178509
6.

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.

PMID:
12788877
7.
8.

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.

PMID:
14557471
9.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
10.

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.

PMID:
8960841
12.

Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.

Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsbøll T.

J Clin Endocrinol Metab. 2009 Dec;94(12):4679-87. doi: 10.1210/jc.2009-0921. Epub 2009 Oct 16.

PMID:
19837930
13.

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.

Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1038-46. doi: 10.1152/ajpendo.00665.2010. Epub 2011 Mar 8.

14.

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM.

Diabetes Nutr Metab. 2004 Dec;17(6):336-42.

PMID:
15887627
15.

The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.

Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A.

Int J Obes Relat Metab Disord. 2001 Aug;25(8):1206-14.

PMID:
11477506
16.

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.

PMID:
8725855
17.

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W.

Diabetologia. 1993 Aug;36(8):741-4.

PMID:
8405741
18.

Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.

Hare KJ.

Dan Med Bull. 2010 Sep;57(9):B4181.

PMID:
20816021
19.
20.

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

Egan JM, Meneilly GS, Habener JF, Elahi D.

J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73.

PMID:
12161508

Supplemental Content

Support Center